CA2608271C - Facteur viii de croissance epidermique de globule de matiere grasse de lait et sepsis - Google Patents
Facteur viii de croissance epidermique de globule de matiere grasse de lait et sepsis Download PDFInfo
- Publication number
- CA2608271C CA2608271C CA2608271A CA2608271A CA2608271C CA 2608271 C CA2608271 C CA 2608271C CA 2608271 A CA2608271 A CA 2608271A CA 2608271 A CA2608271 A CA 2608271A CA 2608271 C CA2608271 C CA 2608271C
- Authority
- CA
- Canada
- Prior art keywords
- mfg
- sepsis
- mammal
- seq
- milk fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 91
- 229960000301 factor viii Drugs 0.000 title claims abstract description 25
- 108010071421 milk fat globule Proteins 0.000 title claims abstract description 25
- 241000124008 Mammalia Species 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims abstract description 39
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 210000001808 exosome Anatomy 0.000 claims description 42
- 210000002966 serum Anatomy 0.000 claims description 26
- 230000001766 physiological effect Effects 0.000 claims description 17
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 241000894007 species Species 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 7
- 230000035939 shock Effects 0.000 claims description 6
- 101800004937 Protein C Proteins 0.000 claims description 5
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims description 5
- 101800001700 Saposin-D Proteins 0.000 claims description 5
- 239000000674 adrenergic antagonist Substances 0.000 claims description 5
- 229960000856 protein c Drugs 0.000 claims description 5
- 102000004379 Adrenomedullin Human genes 0.000 claims description 4
- 101800004616 Adrenomedullin Proteins 0.000 claims description 4
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical group C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 claims description 4
- 102000034273 adrenomedullin binding proteins Human genes 0.000 claims description 4
- 108091000485 adrenomedullin binding proteins Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 abstract description 28
- 102100039648 Lactadherin Human genes 0.000 abstract 1
- 101710191666 Lactadherin Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 18
- 206010057249 Phagocytosis Diseases 0.000 description 15
- 230000008782 phagocytosis Effects 0.000 description 15
- 230000001640 apoptogenic effect Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 102100040247 Tumor necrosis factor Human genes 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 101001034321 Mus musculus Lactadherin Proteins 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000000816 peptidomimetic Substances 0.000 description 7
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 102000051386 human MFGE8 Human genes 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000026727 thymocyte apoptotic process Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004952 protein activity Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010018873 Haemoconcentration Diseases 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- -1 for example Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000036513 peripheral conductance Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101001034301 Rattus norvegicus Lactadherin Proteins 0.000 description 1
- 101100076832 Rattus norvegicus Mfge8 gene Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000025194 apoptotic cell clearance Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne un procédé de traitement d'un mammifère atteint de sepsis ou présentant un risque de sepsis. Cette invention concerne aussi des procédés de prévention ou de traitement d'effet physiologique de sepsis chez un mammifère. Cette invention concerne aussi l'utilisation de facteur VIII (MFG- E8) de facteur croissance épidermique de globule de matière grasse de lait permettant la fabrication d'un médicament destiné à prévention ou au traitement d'un effet physiologique de sepsis chez un mammifère et, l'utilisation de facteur VIII (MFG-E8) de facteur de croissance de matière grasse de lait dans le traitement d'un mammifère atteint de sepsis ou présentant un risque de sepsis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68062805P | 2005-05-13 | 2005-05-13 | |
| US60/680,628 | 2005-05-13 | ||
| PCT/US2006/018774 WO2006122327A2 (fr) | 2005-05-13 | 2006-05-12 | Facteur viii de croissance epidermique de globule de matiere grasse de lait et sepsis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2608271A1 CA2608271A1 (fr) | 2006-11-16 |
| CA2608271C true CA2608271C (fr) | 2016-01-19 |
Family
ID=37397353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2608271A Active CA2608271C (fr) | 2005-05-13 | 2006-05-12 | Facteur viii de croissance epidermique de globule de matiere grasse de lait et sepsis |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9321822B2 (fr) |
| EP (1) | EP1888096B1 (fr) |
| CN (1) | CN101203234B (fr) |
| AU (1) | AU2006243905B2 (fr) |
| CA (1) | CA2608271C (fr) |
| WO (1) | WO2006122327A2 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005231395B2 (en) | 2004-03-31 | 2011-06-16 | The Fernstein Institute For Medical Research | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment |
| US8703693B2 (en) * | 2004-03-31 | 2014-04-22 | The Feinstein Institute For Medical Research | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment |
| ES2880460T3 (es) * | 2006-03-09 | 2021-11-24 | Aethlon Medical Inc | Eliminación extracorpórea de partículas microvesiculares |
| EP2215264B1 (fr) * | 2007-11-15 | 2015-04-01 | The Feinstein Institute for Medical Research | Prévention et traitement d'inflammation et de lésion d'organe après ischémie/reperfusion en utilisant mfg-e8 |
| CN101705288B (zh) * | 2009-11-17 | 2011-12-28 | 西北农林科技大学 | 奶山羊mfg-e8基因的单核苷酸多态性及其检测方法 |
| CN101705290B (zh) * | 2009-11-17 | 2011-12-28 | 西北农林科技大学 | 奶山羊scd基因的单核苷酸多态性及其检测方法 |
| WO2012149254A2 (fr) * | 2011-04-28 | 2012-11-01 | The Feinstein Institute For Medical Research | Mfg-e8 et ses utilisations |
| DK2808028T3 (da) * | 2011-11-21 | 2019-10-07 | Univ Tsukuba | Aktivitetsmodulator, medicinsk middel omfattende samme, anvendelse af mus med cd300a-gen-mangel og anti-cd300a antistof |
| WO2014073529A1 (fr) | 2012-11-07 | 2014-05-15 | 国立大学法人筑波大学 | MÉDICAMENT COMPRENANT UN MODULATEUR DE L'ACTIVITÉ D'UNE CELLULE EXPRIMANT LE CD300a ASSOCIÉE À UNE MALADIE ALLERGIQUE, SOURIS PRÉSENTANT UNE INACTIVATION DU GÈNE CD300a, ET UTILISATION DU MODULATEUR DE L'ACTIVITÉ DE LA CELLULE EXPRIMANT LE CD300a |
| US9669070B2 (en) | 2013-09-17 | 2017-06-06 | The Feinstein Institute For Medical Research | Treatment and prevention of radiation injury using MFG-E8 |
| WO2016179417A2 (fr) * | 2015-05-06 | 2016-11-10 | The University Of Utah Research Foundation | Administration d'exosomes de micro-arn |
| EP4025237A1 (fr) | 2019-09-06 | 2022-07-13 | Novartis AG | Protéines de fusion thérapeutiques |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004664A1 (fr) | 1998-11-24 | 2000-05-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions et procédés utilisant la lactadhérine ou des dérivés de celle-ci |
| EP1417229B1 (fr) * | 2001-08-17 | 2011-06-15 | Exothera L.L.C. | Procedes et composes pour le ciblage de proteines vers des exosomes |
| JP4160292B2 (ja) * | 2001-11-20 | 2008-10-01 | 独立行政法人科学技術振興機構 | 生体内のアポトーシス細胞の除去促進剤及び除去阻害剤 |
| US7354897B2 (en) * | 2002-06-07 | 2008-04-08 | Brigham & Women's Hospital, Inc. | Method and composition for inhibiting or slowing blood coagulation |
| EP2215264B1 (fr) | 2007-11-15 | 2015-04-01 | The Feinstein Institute for Medical Research | Prévention et traitement d'inflammation et de lésion d'organe après ischémie/reperfusion en utilisant mfg-e8 |
| WO2012149254A2 (fr) | 2011-04-28 | 2012-11-01 | The Feinstein Institute For Medical Research | Mfg-e8 et ses utilisations |
-
2006
- 2006-05-12 AU AU2006243905A patent/AU2006243905B2/en not_active Ceased
- 2006-05-12 CN CN2006800223836A patent/CN101203234B/zh not_active Expired - Fee Related
- 2006-05-12 WO PCT/US2006/018774 patent/WO2006122327A2/fr active Application Filing
- 2006-05-12 EP EP06784414.2A patent/EP1888096B1/fr not_active Not-in-force
- 2006-05-12 US US11/920,304 patent/US9321822B2/en not_active Expired - Fee Related
- 2006-05-12 CA CA2608271A patent/CA2608271C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006122327A8 (fr) | 2007-05-24 |
| US9321822B2 (en) | 2016-04-26 |
| EP1888096B1 (fr) | 2017-12-27 |
| AU2006243905A1 (en) | 2006-11-16 |
| EP1888096A2 (fr) | 2008-02-20 |
| CA2608271A1 (fr) | 2006-11-16 |
| AU2006243905B2 (en) | 2011-09-01 |
| US20090297498A1 (en) | 2009-12-03 |
| WO2006122327A2 (fr) | 2006-11-16 |
| EP1888096A4 (fr) | 2009-08-26 |
| CN101203234B (zh) | 2012-10-10 |
| WO2006122327A3 (fr) | 2007-12-13 |
| CN101203234A (zh) | 2008-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2608271C (fr) | Facteur viii de croissance epidermique de globule de matiere grasse de lait et sepsis | |
| US8518883B2 (en) | Method of reducing deleterious effects of ischemia by administration of a thrombopoietin receptor ligand | |
| US20140121163A1 (en) | Mfg-e8 and uses thereof | |
| RU2592983C2 (ru) | Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака | |
| CN113248628B (zh) | 一种乳源多肽衍生物及其在制备肥胖症防治药物、保健品和食品添加物中的应用 | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| EP3881856A1 (fr) | Composition pharmaceutique destinée au traitement de l'anémie aplasique | |
| US9101593B2 (en) | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment | |
| Porten et al. | Candidiasis endocrinopathy syndrome | |
| KR20200067745A (ko) | Fas 신호전달 억제용 펩티드를 포함하는 비만, 지방간 또는 지방간염의 예방 또는 치료용 약학적 조성물 | |
| US8703693B2 (en) | Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment | |
| JP2000506502A (ja) | ヒアルロン酸レセプター結合剤、およびその使用方法 | |
| US20210315897A1 (en) | The combination of xpo1 inhibitors and second agents for the treatment of prostate cancer | |
| US20070004625A1 (en) | Use of complement inhibitory proteins to treat spinal cord injury | |
| US10441631B2 (en) | Therapeutic agent for amniotic fluid embolism | |
| CN115884783A (zh) | Ghrh类似物的低剂量药物组合物及其用途 | |
| KR20230095665A (ko) | 간 표적 약물 및 이의 용도 | |
| AU2005202872A1 (en) | Use of complement inhibitory proteins to treat spinal cord injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |